New Two-Drug attack on stubborn blood cancer
NCT ID NCT05723055
Summary
This study is testing a combination of two immunotherapy drugs, nivolumab and axatilimab, for adults with classical Hodgkin lymphoma that has come back or hasn't responded to previous treatments, including similar immunotherapies. The main goals are to see if the combination is safe and if it can shrink or eliminate tumors. Up to 12 participants will receive the treatment for up to a year to measure its effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at the University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.